| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | SOLIGENIX, INC. | SUITE C-10 | PRINCETON | NJ | 08540-5919 | MERCER | USA | R44AI157593 | Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP | 000 | 2 | NIH | 7/22/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $829,746 ) |
| | 2022 | 2022 | SOLIGENIX, INC. | 29 EMMONS DR STE B10 | PRINCETON | NJ | 08540-5950 | MERCER | USA | R44AI157593 | Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP | 001 | 2 | NIH | 7/1/2022 | $0 |
| | 2022 | 2022 | SOLIGENIX, INC. | 29 EMMONS DR STE B10 | PRINCETON | NJ | 08540-5950 | MERCER | USA | R44AI157593 | Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP | 000 | 2 | NIH | 11/22/2021 | $829,746 |
|
| Issue Date FY: 2021 ( Subtotal = $636,664 ) |
| | 2021 | 2021 | SOLIGENIX, INC. | 29 EMMONS DR STE B10 | PRINCETON | NJ | 08540-5950 | MERCER | USA | R44AI157593 | Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP | 000 | 1 | NIH | 12/17/2020 | $636,664 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2018 | SOLIGENIX, INC. | 29 EMMONS DR STE B10 | PRINCETON | NJ | 08540-5950 | MERCER | USA | R44CA210848 | Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma | 000 | 2 | NIH | 6/16/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $150,000 ) |
| | 2019 | 2019 | SOLIGENIX, INC. | 29 EMMONS DR STE B10 | PRINCETON | NJ | 08540-5950 | MERCER | USA | R43DE028769 | "Dusquetide for the treatment of oral mucositis in the pediatric population" | 000 | 1 | NIH | 8/14/2019 | $150,000 |
| | 2019 | 2018 | SOLIGENIX, INC. | 29 EMMONS DR STE B10 | PRINCETON | NJ | 08540-5950 | MERCER | USA | R44DE024032 | SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer | 000 | 3 | NIH | 9/25/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,498,530 ) |
| | 2018 | 2018 | SOLIGENIX, INC. | 29 EMMONS DR STE B10 | PRINCETON | NJ | 08540-5950 | MERCER | USA | R44DE024032 | SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer | 000 | 3 | NIH | 8/24/2018 | $750,000 |
| | 2018 | 2018 | SOLIGENIX, INC. | 29 EMMONS DR STE B10 | PRINCETON | NJ | 08540-5950 | MERCER | USA | R44CA210848 | Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma | 000 | 2 | NIH | 8/24/2018 | $750,000 |
| | 2018 | 2014 | SOLIGENIX, INC. | 29 EMMONS DR STE B10 | PRINCETON | NJ | 08540-5950 | MERCER | USA | R43AI108175 | Innate Defense Regulator Peptide as a Therapeutic for Acute Pneumonic Melioidosis | 000 | 1 | NIH | 3/7/2018 | -$1,470 |
|
| Issue Date FY: 2017 ( Subtotal = $1,464,817 ) |
| | 2017 | 2017 | SOLIGENIX, INC. | 29 EMMONS DR STE C10 | PRINCETON | NJ | 08540-5919 | MERCER | USA | R44DE024032 | SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer | 000 | 2 | NIH | 9/13/2017 | $714,260 |
| | 2017 | 2017 | SOLIGENIX, INC. | 29 EMMONS DR STE C10 | PRINCETON | NJ | 08540-5919 | MERCER | USA | R44DE024032 | SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer | 001 | 2 | NIH | 9/25/2017 | $557 |
| | 2017 | 2017 | SOLIGENIX, INC. | 29 EMMONS DR STE C10 | PRINCETON | NJ | 08540-5919 | MERCER | USA | R44CA210848 | Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma | 000 | 1 | NIH | 9/14/2017 | $750,000 |
|
| Issue Date FY: 2015 ( Subtotal = $0 ) |
| | 2015 | 2014 | SOLIGENIX INC | 1691 michigan ave, ste 436 | MIAMI | NJ | 08540 | | USA | R43AI108175 | Innate Defense Regulator Peptide as a Therapeutic for Acute Pneumonic Melioidosis | 000 | 1 | NIH | 5/6/2015 | $0 |
| | 2015 | 2012 | SOLIGENIX INC | 1691 michigan ave, ste 436 | MIAMI | NJ | 08540 | | USA | R01FD003544 | IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0 | 000 | 3 | FDA | 12/29/2014 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $525,000 ) |
| | 2014 | 2014 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R43AI108175 | Innate Defense Regulator Peptide as a Therapeutic for Acute Pneumonic Melioidosis | 000 | 1 | NIH | 2/13/2014 | $300,000 |
| | 2014 | 2014 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R43DE024032 | SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer | 001 | 1 | NIH | 9/25/2014 | $22,500 |
| | 2014 | 2014 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R43DE024032 | SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer | 000 | 1 | NIH | 4/4/2014 | $202,500 |
|
| Issue Date FY: 2013 ( Subtotal = $1,626,780 ) |
| | 2013 | 2013 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R43CA162619 | IND 20212 (03-25-99) PHASE 2: ORBEC (ORAL BDP)-PATIENTS WITH CHRONIC GVHD | 000 | 2 | NIH | 8/13/2013 | $144,150 |
| | 2013 | 2013 | SOLIGENIX INC | 1691 michigan ave, ste 436 | MIAMI | NJ | 08540 | | USA | R43AI100417 | BECLOMETHASONE POST EXPOSURE THERAPY FOR GASTROINTESTINAL ACUTE RADIATION SYNDROM | 001 | 2 | NIH | 8/30/2013 | -$300,000 |
| | 2013 | 2013 | SOLIGENIX INC | 1691 michigan ave, ste 436 | MIAMI | NJ | 08540 | | USA | R43AI100417 | BECLOMETHASONE POST EXPOSURE THERAPY FOR GASTROINTESTINAL ACUTE RADIATION SYNDROM | 001 | 2 | NIH | 8/30/2013 | $300,000 |
| | 2013 | 2013 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | U01AI082210 | DEVELOPMENT OF STABLE AND RAPIDLY ACTING ADJUVANTED VACCINES FOR BIODEFENSE | 000 | 5 | NIH | 8/7/2013 | $1,182,630 |
| | 2013 | 2013 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R43AI100417 | BECLOMETHASONE POST EXPOSURE THERAPY FOR GASTROINTESTINAL ACUTE RADIATION SYNDROM | 000 | 2 | NIH | 6/14/2013 | $300,000 |
|
| Issue Date FY: 2012 ( Subtotal = $1,879,151 ) |
| | 2012 | 2012 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R01FD003544 | IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0 | 000 | 3 | FDA | 8/31/2012 | $87,803 |
| | 2012 | 2012 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | U01AI082210 | DEVELOPMENT OF STABLE AND RAPIDLY ACTING ADJUVANTED VACCINES FOR BIODEFENSE | 000 | 4 | NIH | 8/15/2012 | $1,341,348 |
| | 2012 | 2012 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R43AI100417 | BECLOMETHASONE POST EXPOSURE THERAPY FOR GASTROINTESTINAL ACUTE RADIATION SYNDROM | 000 | 1 | NIH | 7/16/2012 | $300,000 |
| | 2012 | 2012 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R43CA162619 | IND 20212 (03-25-99) PHASE 2: ORBEC (ORAL BDP)-PATIENTS WITH CHRONIC GVHD | 000 | 1 | NIH | 8/28/2012 | $150,000 |
|
| Issue Date FY: 2011 ( Subtotal = $3,733,529 ) |
| | 2011 | 2011 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R01FD003544 | IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0 | 002 | 2 | FDA | 9/1/2011 | $400,000 |
| | 2011 | 2011 | SOLIGENIX INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | U01AI082210 | DEVELOPMENT OF STABLE AND RAPIDLY ACTING ADJUVANTED VACCINES FOR BIODEFENSE | 000 | 3 | NIH | 8/18/2011 | $3,333,529 |
| | 2011 | 2010 | SOLIGENIX INC | 1691 michigan ave, ste 436 | MIAMI | NJ | 08540 | | USA | R01FD003544 | IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0 | 001 | 1 | FDA | 6/23/2011 | $0 |
| | 2011 | 2010 | SOLIGENIX INC | 1691 michigan ave, ste 436 | MIAMI | NJ | 08540 | | USA | R01FD003544 | IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0 | 000 | 1 | FDA | 5/5/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $2,549,739 ) |
| | 2010 | 2010 | DOR BIOPHARAMA INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R43CA141968 | ENTERIC-COATED ORAL BECLOMETHASONE DIPROPIONATE IN PATIENTS WITH ACUTE ENTERITIS | 001 | 2 | NIH | 8/16/2010 | $258,635 |
| | 2010 | 2010 | DOR BIOPHARAMA INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | R01FD003544 | IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0 | 000 | 1 | FDA | 8/24/2010 | $400,000 |
| | 2010 | 2010 | DOR BIOPHARAMA INC | 1691 michigan ave, ste 436 | miami | FL | 33139-2520 | | USA | U01AI082210 | DEVELOPMENT OF STABLE AND RAPIDLY ACTING ADJUVANTED VACCINES FOR BIODEFENSE | 001 | 2 | NIH | 8/23/2010 | $1,891,104 |
| | 2010 | 2009 | SOLIGENIX INC | 1691 michigan ave, ste 436 | MIAMI | NJ | 08540 | | USA | U01AI082210 | DEVELOPMENT OF STABLE AND RAPIDLY ACTING ADJUVANTED VACCINES FOR BIODEFENSE | 000 | 1 | NIH | 11/25/2009 | $0 |
| | 2010 | 2009 | SOLIGENIX INC | 1691 michigan ave, ste 436 | MIAMI | NJ | 08540 | | USA | R43CA141968 | ENTERIC-COATED ORAL BECLOMETHASONE DIPROPIONATE IN PATIENTS WITH ACUTE ENTERITIS | 000 | 1 | NIH | 3/6/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $1,556,996 ) (Continued on the next page) |
|
